Last Updated: 14 Nov 2024
Executive Summary
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company focused on developing proprietary cancer therapies. Despite a lack of profitability, the company's strong balance sheet and promising pipeline support its current valuation. With a market capitalization of $91.04 million and an analyst target price of $15.33, MNPR presents a compelling investment opportunity for long-term growth.
Company Overview
Monopar Therapeutics is headquartered in Wilmette, Illinois, and is dedicated to improving clinical outcomes for cancer patients in the United States. The company's research and development efforts are centered on developing novel therapies that target specific molecular pathways involved in cancer growth and progression.
Fundamental Analysis
Revenue: MNPR has yet to generate any revenue, as its products are still in the clinical development stage.
Earnings: The company reported a loss per share of $2.30 for the latest quarter.
Profitability: MNPR has negative profit margins and operating margins, indicating that it is not yet profitable.
Balance Sheet: The company has a strong balance sheet with $18.75 million in cash and no debt.
Book Value: MNPR's book value per share is $1.875.
Price-to-Book Ratio: The stock is currently trading at a price-to-book ratio of 15.3, which is relatively high.
Technical Analysis
52-Week High/Low: The stock's 52-week high is $38.50, while its 52-week low is $1.37.
Moving Averages: The stock's 50-day moving average is $7.84, and its 200-day moving average is $4.47.
Beta: MNPR's beta is 1.104, indicating that it is slightly more volatile than the overall market.
Short Term Outlook
In the short term, MNPR's stock price could experience volatility due to the lack of revenue and profitability. However, positive news regarding clinical trials or partnerships could provide a catalyst for growth.
Long Term Outlook
The long-term outlook for MNPR is promising. The company's strong balance sheet and promising pipeline provide a solid foundation for future growth. If MNPR can successfully develop and commercialize its therapies, it has the potential to become a major player in the oncology market.
Analyst Recommendations
Out of the analysts covering MNPR, 3 recommend buying the stock, while 0 recommend holding or selling. The average analyst target price is $15.33.
